New drug duo targets tough KRAS mutation in advanced cancers
Disease control
Recruiting now
This study tests two experimental drugs, IN10018 and RNK08954, given together to people with advanced solid tumors that have a specific KRAS G12D gene change. The goal is to find the best dose and see if the combination can shrink tumors. About 92 adults with locally advanced or …
Phase: PHASE1, PHASE2 • Sponsor: InxMed (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Apr 29, 2026 06:26 UTC